Answers are grounded in this paper and cite their sources.
Case report reveals rheumatic fever and Sydenham chorea in a child on infliximab for Crohn disease, suggesting anti-TNF therapy may not prevent post-streptococcal autoimmunity.
We present a case of a young female patient with Crohn disease receiving infliximab treatment, who developed rheumatic fever despite apparently adequate antibiotic treatment. Both Crohn disease and rheumatic fever are autoimmune disorders. Tumor necrosis factor (TNF)-α plays a role in both entities. Infliximab as anti-TNF-α treatment should prevent the development of rheumatic fever; interestingly, that was not the case in our patient. CASE REPORT A 10-year-old girl was diagnosed with terminal ileal Crohn disease 3 years before the present illness. After initial treatment with prednisone, she was treated with azathioprine and oral mesalamine but experienced multiple relapses requiring oral prednisone therapy. Esophagogastroduodenoscopy and colonoscopy were performed before planned infliximab therapy, demonstrating esophagitis, gastritis, duodenitis, and severe terminal ileitis with linear ulcers. Helicobacter pylori was detected in the stomach, which was treated with clarithromycin, metronidazole, and omeprazole. Because her symptoms of bloody diarrhea and cramping continued, she was given infliximab. She received 5 mg/kg at 0, 2, and 6 weeks for induction, and prednisone was tapered. Her symptoms rapidly improved. Two weeks before her third induction infusion, she presented to her primary care physician with fever up to 38.9°C, headache, and malaise. Pharyngitis was noted on examination, and a rapid streptococcal antigen test was positive. Because of penicillin allergy, she was given azithromycin. Five days into the azithromycin treatment, she remained febrile and symptomatic. A repeat streptococcal antigen test remained positive. Azithromycin was discontinued and a 10-day course of clindamycin was begun. Her symptoms resolved. At the time of her third infliximab induction treatment, she had completed 8 days of clindamycin therapy. Infliximab was given without complications, and she was instructed to return in 8 weeks for maintenance infliximab therapy. When she returned for her first scheduled maintenance infusion, the mother reported that she had been emotionally labile for the previous week. The mother described her being fidgety with facial twitching, blinking of the right eye, and having sudden, involuntary arm movements that she could not control. The child would also drop items unexpectedly and complained of numbness in her right hand. The scheduled infliximab infusion was held. She had a brain magnetic resonance imaging (MRI) done that day to look for anomalies and rule out any evidence of demyelinating disease. This study was normal, except for an incidental pineal cyst that was stable compared with an examination the year before. Her neurological examination at that time revealed normal visual acuity, normal visual fields, and fundoscopic examination that was normal bilaterally. Her cranial nerve examination was normal. The tone, strength, and bulk of her muscles were normal in all distributions. She did have frequent motor overflow and choreiform movements in right more than in left hand, neck, head, and even legs, these were exacerbated with intended movements. She had dystonic-like posturing of her right more than her left extremities with performance of stressed gait or other motor activities. Sensation, gait, and coordination were intact. With the history of streptococcal infection and her physical examination, the impression was that she had rheumatic fever with Sydenham chorea. The child was evaluated by pediatric cardiology the next day. Her physical examination was consistent with mitral regurgitation. Her electrocardiogram demonstrated sinus rhythm with prolonged PR interval at 168 ms, consistent with carditis, and her echocardiogram demonstrated moderate mitral valve regurgitation. Laboratory testing sent at that time was significant for a negative rapid streptococcal antigen test and culture. Erythrocyte sedimentation rate was 45 mm/h (0–20), C-reactive protein 1.0 mg/dL (<0.5), anti-streptolysin antibody 1600 (0–240), and DNase B antibody 2680 (0–170). The anti-nuclear antibody was slightly elevated at 1:160 with a nucleosomal pattern. Anti-double-stranded DNA, anti-Smith, anti-ribonucleoprotein, and anti-cardiolipin antibodies were normal. Hemolytic complement-50 was elevated >60. C3, C4, Ro, and La antibodies were within normal limits. A diagnosis of rheumatic fever was made, and she was given aspirin 375 mg 4 times per day and valproic acid to suppress her chorea. Cephalexin was also given for 10 days, followed by daily macrolide therapy for rheumatic fever prophylaxis. She was followed closely and finally received her fourth infliximab infusion 6 weeks after the original scheduled date. This was tolerated well, with no recurrence of rheumatic symptoms. Her chorea and associated emotional lability resolved, and a gradual taper of the valproic acid therapy was instituted. DISCUSSION Our patient presented with Sydenham chorea and carditis while receiving infliximab therapy for Crohn disease. This occurred despite being treated with appropriate antibiotics for group A β- hemolytic Streptococcus pyogenes pharyngitis and penicillin allergy. Chorea following pharyngitis was first described by Thomas Sydenham in 1686. The association with rheumatic fever has been recognized since 1956 (1). Sydenham chorea is a major criterion of rheumatic fever and is, in fact, sufficient by itself as a criterion for diagnosis, according to the current modified Jones criteria (2). Sydenham chorea is a frequent manifestation of rheumatic fever. In 1 recent study (3), it was the presenting manifestation of rheumatic fever in 30% of cases. Of all of the patients who presented with chorea as the first symptom, 60% had carditis in association with it. Recurrent rheumatic disease occurred in 20% of all of the treated patients and chorea manifested in up to 63% of all of the recurrences (3). When our patient presented with neurological symptoms after 3 induction doses of infliximab, our first concern was to rule out a demyelinating disorder as a side effect of infliximab (4). Fortunately, her brain MRI was normal. We also needed to exclude lupus because infliximab has been associated with drug-induced lupus (5). Our patient's workup was negative for lupus, and she had a well-documented alternative explanation for rheumatic fever. Because our patient was allergic to penicillin, she had been treated initially with 5 days of azithromycin and then a 10-day course of clindamycin because of persistent infection. Both azithromycin and clindamycin are accepted treatments of streptococcal pharyngitis for patients with penicillin allergy (6,14). The prevalence of clindamycin-resistant strains of group A β-hemolytic S pyogenes is only about 1% in the United States, whereas macrolide-resistant strains can be as high as 5% to 8% (6). Our patient developed rheumatic fever even though she was appropriately treated. The mother was certain that the child had received all of the prescribed doses of antibiotic. This child's streptococcal infection occurred about 2 weeks before her third infliximab induction dose. She had received the full course of azithromycin and then 8 additional days of clindamycin and was asymptomatic when she had received the third dose of infliximab. The question we subsequently struggled with was whether the infliximab had influenced the development of rheumatic fever. The chorea appeared 2 months after onset of her streptococcal pharyngitis. Although it is common for chorea to present 1 to 6 months after the acute streptococcal infection, carditis and arthritis usually present within 1 to 3 weeks of the infection (2,7,8). A possible explanation for this atypical presentation is the fact that the patient was receiving infliximab. TNF-α is one of the main cytokines produced by lymphocytes in the peripheral blood after the S pyogenes infection, along with interleukin (IL)-1 and IL-6. The mechanism of disease in rheumatic fever is thought to be molecular mimicry to streptococcus. S pyogenes expresses antigens similar to those found on various human cells, such as cardiac myocytes, resulting in an overactive immune response that targets self-tissues. The mechanism of injury includes activation of T-cell lymphocytes to secrete cytokines, which again includes TNF-α and interferon, along with ILs (9). This results in tissue injury and an intense inflammatory reaction. Infliximab should theoretically inhibit the TNF-α–related components of the inflammation and should therefore be protective. This has been described as the main mechanism of action of this drug (10). Perplexing enough, our patient developed a TNF-α–mediated disease while receiving a TNF-α inhibitor medication. An alternative explanation for the rheumatic fever is that infliximab therapy resulted in an impaired immune response against the streptococcus, resulting in an infection that could not be completely eradicated despite antibiotic therapy. Few case reports have linked infections such as streptococcal meningitis or pneumococcal pneumonia in patients with the use of infliximab (11,12). Whether infliximab increased the patients’ susceptibility to opportunistic infections or promoted resistance to standard protocols for therapy while receiving infliximab is unclear. Such resistance or delayed responses to treatment has also been reported in a patient with tuberculosis while receiving infliximab therapy (13). After consulting with pediatric cardiology, infectious disease, rheumatology, and neurology, we elected to continue our patient on infliximab infusions every 8 weeks. She had complete resolution of her neurological symptoms at her first follow-up visit, 1 month after diagnosis. Hence, her first maintenance dose was given and was well tolerated. She has subsequently been studied for 2 more months and received a second maintenance dose at the time of this writing, with no additional rheumatic symptoms and continued excellent control of her Crohn disease. We plan to perform serial brain MRI studies at least every 6 months until we can be confident that there is no evidence of further central nervous system disease. We recommend long-term antibiotic therapy to suppress future streptococcal infections (14). CONCLUSIONS Our patient developed rheumatic fever despite receiving adequate treatment for S pyogenes. We postulate that our patient's rheumatic fever was not caused by infliximab therapy, but that the delayed manifestation of rheumatic fever may have been related to anti-TNF-α treatment. We conclude that it is most likely that an antibiotic-resistant organism was responsible for the development of rheumatic fever. Nevertheless, clinicians should be alert to the possibility of an association between rheumatic fever and infliximab therapy.
No takes yet. Share an insight, caveat, or question.
Abu‐El‐Haija et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: